vs
Side-by-side financial comparison of GATX CORP (GATX) and Bio-Techne (TECH). Click either name above to swap in a different company.
GATX CORP is the larger business by last-quarter revenue ($436.7M vs $311.4M, roughly 1.4× Bio-Techne). GATX CORP runs the higher net margin — 18.1% vs 16.4%, a 1.7% gap on every dollar of revenue. On growth, GATX CORP posted the faster year-over-year revenue change (38.4% vs -1.5%). Over the past eight quarters, GATX CORP's revenue compounded faster (6.3% CAGR vs 1.3%).
GATX Corporation is a railcar lessor that owns fleets in North America, Europe, and Asia. In addition, jointly with Rolls-Royce Limited, it owns one of the largest aircraft spare engine lease portfolios. It is headquartered in Chicago, Illinois. As of December 31, 2020, the company owned 148,939 rail cars, including 83,959 tank cars, 64,980 freight cars, and 645 locomotives. Other major car types owned include covered hoppers, open-top hopper cars, and gondolas. It primarily serves the petrol...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GATX vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $436.7M | $311.4M |
| Net Profit | $79.1M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 18.1% | 16.4% |
| Revenue YoY | 38.4% | -1.5% |
| Net Profit YoY | 0.6% | 126.0% |
| EPS (diluted) | $2.35 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $436.7M | $311.4M | ||
| Q4 25 | $449.0M | $295.9M | ||
| Q3 25 | $439.3M | — | ||
| Q2 25 | $430.5M | $317.0M | ||
| Q1 25 | $421.6M | $316.2M | ||
| Q4 24 | $413.5M | $297.0M | ||
| Q3 24 | $405.4M | $289.5M | ||
| Q2 24 | $386.7M | $306.1M |
| Q1 26 | $79.1M | $51.0M | ||
| Q4 25 | $97.0M | $38.0M | ||
| Q3 25 | $82.2M | — | ||
| Q2 25 | $75.5M | $-17.7M | ||
| Q1 25 | $78.6M | $22.6M | ||
| Q4 24 | $76.5M | $34.9M | ||
| Q3 24 | $89.0M | $33.6M | ||
| Q2 24 | $44.4M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 15.6% | 18.4% | ||
| Q3 25 | 13.3% | — | ||
| Q2 25 | 18.7% | -7.5% | ||
| Q1 25 | 16.6% | 12.2% | ||
| Q4 24 | 14.6% | 16.0% | ||
| Q3 24 | 21.1% | 13.8% | ||
| Q2 24 | 10.9% | 15.0% |
| Q1 26 | 18.1% | 16.4% | ||
| Q4 25 | 21.6% | 12.8% | ||
| Q3 25 | 18.7% | — | ||
| Q2 25 | 17.5% | -5.6% | ||
| Q1 25 | 18.6% | 7.1% | ||
| Q4 24 | 18.5% | 11.7% | ||
| Q3 24 | 22.0% | 11.6% | ||
| Q2 24 | 11.5% | 13.3% |
| Q1 26 | $2.35 | $0.32 | ||
| Q4 25 | $2.66 | $0.24 | ||
| Q3 25 | $2.25 | — | ||
| Q2 25 | $2.06 | $-0.11 | ||
| Q1 25 | $2.15 | $0.14 | ||
| Q4 24 | $2.11 | $0.22 | ||
| Q3 24 | $2.43 | $0.21 | ||
| Q2 24 | $1.21 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $740.9M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7B | $2.1B |
| Total Assets | $17.9B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $740.9M | $209.8M | ||
| Q4 25 | $743.0M | $172.9M | ||
| Q3 25 | $696.1M | — | ||
| Q2 25 | $754.6M | $162.2M | ||
| Q1 25 | $757.2M | $140.7M | ||
| Q4 24 | $401.6M | $177.5M | ||
| Q3 24 | $503.7M | $187.5M | ||
| Q2 24 | $823.6M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $12.5B | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $8.3B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $3.7B | $2.1B | ||
| Q4 25 | $2.8B | $2.0B | ||
| Q3 25 | $2.7B | — | ||
| Q2 25 | $2.7B | $1.9B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.4B | $2.1B | ||
| Q3 24 | $2.4B | $2.1B | ||
| Q2 24 | $2.3B | $2.1B |
| Q1 26 | $17.9B | $2.6B | ||
| Q4 25 | $18.0B | $2.5B | ||
| Q3 25 | $13.3B | — | ||
| Q2 25 | $13.2B | $2.6B | ||
| Q1 25 | $13.0B | $2.6B | ||
| Q4 24 | $12.3B | $2.7B | ||
| Q3 24 | $12.4B | $2.7B | ||
| Q2 24 | $12.2B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 4.55× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 3.39× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GATX
| Lease revenue | $400.7M | 92% |
| Other revenue | $36.0M | 8% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
